潰瘍性大腸炎の治療におけるウステキヌマブの有効性と安全性: 系統的レビュー
Yashasvi Agarwal1, Nehal K Bhatt2, Samyuktha Harikrishnan3
1Internal Medicine, Jawaharlal Nehru Medical College, Belagavi, IND.
Cureus
|September 2, 2025
まとめ
Ustekinumab (UST) は,中度から重度の潰瘍性大腸炎 (UC) の寛解を効果的に誘導し維持します. 治療が難しいUC患者に対して,標的治療の選択肢を提供している.
科学分野:
- 胃腸内科
- 免疫学
- 薬理学について
背景:
- 潰瘍性大腸炎 (UC) は慢性的な免疫媒介疾患で,長期の治療が必要である.
- 現在のUC治療にはステロイド,チオプリン,生物学的薬 (抗TNF,抗インテグリン,抗IL-12/23) と小分子が含まれています.
- ウステキヌマブ (UST) は,IL-12/23を標的としたもので,他の治療法に反応しない中等から重度のUCに対する最近の生物学的選択肢である.
研究 の 目的:
- 中度から重度の潰瘍性大腸炎 (UC) の患者におけるウステキヌマブ (UST) の安全性と有効性を体系的に検討する.
- 臨床的および内視的改善と寛解の維持におけるUSTの役割を評価する.
- 治療反応の評価のための潜在的なバイオマーカーを特定する.
主な方法:
- PRISMA 2020のガイドラインに沿った体系的なレビュー.
- PubMed,コクラン図書館,サイエンスダイレクト,Google Scholarで英語の記事を検索する (2020-2025).
- 証拠に基づいた結論を確実にするために,含まれている研究の品質評価.
主要な成果:
- USTは,治療困難で活発なUCの寛解を誘発し維持する優越性を示した.
- マヨスコア,CRP,糞便カルプロテクチン (fCal) の低下は,治療への反応と炎症の減少を示しています.
- ヒスト・エンドスコーピによる粘膜の治癒は,長期の疾患負担の軽減と相関しています.
- 治療中止と悪性発症率に至った安全性イベントは,USTとプラセボの間で類似した.
結論:
- Ustekinumab (UST) は,中等度から重度のUC,特に他の治療法に耐性のある患者にとって,安全で効果的な代替薬です.
- USTは,UCの患者中心の標的治療の開発を支援しています.
- 腸外症状への影響を含め,標準化された投与量,長期的な安全性,および他の生物学的薬に対する比較有効性に関するさらなる研究が必要である.
さらに関連する動画
関連する概念動画
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
201
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
201
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
684
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
684
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185


